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KOBERT L. WILENSKY, MD,* JACK A. ZELLER, MD.‘r MARC WISH, MD, FACC,:k 
MARK TULCHINSKY. MDQ 
Because acute coronary thrombosis can cause unstable 
coronary artery disease, fihrinopeptide A, a reliable 
marker of coagulation activity, may play a role in the 
evaluation of unstable ischemic syndromes. A new method 
of fibrinopeptide A sampling, spot urine normalized to 
urinary creatinine, was evaluated in patients with stable 
and unstable angina pectoris and acute myocardial infarc- 
tion. Serial samples were obtained to characterize the 
changes in urinary fibrinopeptide A levels over time in 
patients with ischemic heart disease. 
Admission values (mean + SD) were similar in the 
control group (3.3 rt 1.4 ng/mg creatinine) and the stahle 
angina group (3.2 f 1.1 ng/mg creatinine) (p = NS). Values 
in the unstable angina group (5.7 + 2.6 ngimg creatiuine) 
were higher than those in the control (p = 0.008) and stable 
angina (p < 0.001) groups. Myocardial infarction admis- 
sion values (8.4 + 10.0 ng/mg creatinine) were higher than 
those in the control (p = 0.005) and stable angina (p < 
0.001) groups, but not higher than those in the unstable 
angina group. Peak values (the highest of multiple samples) 
were higher in the unstable angina group (7.6 ? 5.9 ngimg 
creatinine) than in the stable angina group (4.0 f I.0 ng/mg 
creatinine) (p = 0.04), but not in the control group (4.5 f 
1.9 ng/mg creatinine) (p = 0.056). The two patients with 
unstable angina with the highest peak values subsequently 
exhibited infarction. Peak values in patients with infarction 
Acute intracoronary thrombus formation plays an important 
role in unstable angina and myocardial infarction (l-6). 
Therefore. a biochemical marker of thrombus could be a 
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(44.5 + 60.0 ng/mg creatinine) were significantly higher 
than those in patients with unstable (p = 0.03) or stable 
(p = 0.002) angina and control patients (p < 0.901). 
Urinary fibrinopeptide A levels were elevated in 10 (48%) 
of 21 unstable angina admission samples, 10 (53%) of 19 
unstable angina peak samples, 6 (50%) of 12 myocardial 
infarction admission samples and 10 (91%) of 11 infarction 
peak samples. No patient with stable angina had an ele- 
vated urinary fibrinopeptide A value, and 2 of 12 control 
patients had a slightly elevated peak value. 
This study shows that spot urine fibrinopeptide A levels 
are elevated in virtually all patients with myocardial infarc- 
tion and approximately half of the patients with unstable 
angina. Serial sampling demonstrates dynamic changes in 
fibrinopeptide A levels in patients with myocardial infarc- 
tion. reflecting dynamic thrombin activity. Patients with 
unstable angina whose condition progresses to myocardial 
infarction have been shown to exhibit a similar dynamic 
tendency. Serial spot urinary fibrinopeptide A sampling, an 
easy method of sample acquisition, may be helpful in 
identifying those patients with unstable angina who have 
symptoms due to intracoronary artery thrombus formation 
and who are at the greatest risk of progressing to myocar- 
dial infarction. 
(J Am Co11 Cardial 1989;14:597-603) 
valuable noninvasive technique in the evaluation of unstable 
coronary artery disease (7-l I). 
Fibrinopeptide A is a reliable marker of coagulation 
activity. A peptide produced when fibrinogen is converted to 
fibrin by thrombin. it is an effective index of thrombin 
activity and a direct correlate of fibrin generation. Clinical 
interpretation of plasma fibrinopeptide A measurements has 
been hampered by its rapid plasma clearance (12,13) and the 
technical factors involved in blood sampling that may lead to 
falsely elevated levels (14). Urinary fibrinopeptide A is 
stable. and 24 h urinary librinopeptide A levels correlate 
with plasma levels (15.16). A 24 h urine collection, however. 
is technically cumbersome and masks acute changes in 
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fibrinopeptide A levels. Preliminary results from our labora- 
tory (17) have shown that spot urinary fibrinopeptide A 
levels correlate with simultaneously obtained plasma tibri- 
nopeptide A levels. To evaluate 1) spot urinary fibrinopep- 
tide A levels in patients with unstable ischemic heart dis- 
ease, and 2) changes in urinary fibrinopeptide A levels over 
time, we compared, in a prospective, blinded study, serial 
spot urinary fibrinopeptide A levels in patients with stable 
angina pectoris, unstable angina pectoris and acute myocar- 
dial infarction. 
Methods 
Selection of patients. All patients admitted to the coro- 
nary care unit with the diagnosis of acute myocardial infarc- 
tion (~24 h from symptom onset) or unstable angina pectoris 
were eligible for inclusion in this study. Consecutive patients 
with stable angina pectoris admitted for elective cardiac 
catheterization were also included. Patients were excluded if 
the following conditions, known to increase fibrinopeptide A 
levels (l4), were present: malignancy, infection, noncardiac 
thrombosis or inflammatory disease. Patients with idiopathic 
dilated cardiomyopathy were excluded because of the high 
incidence of mural thrombus. 
Definition of experimental groups. Control: individuals 
without symptoms of cardiac disease or those patients 
admitted to the coronary care unit without evidence of 
coronary artery disease on subsequent exercise stress test or 
coronary angiogram. 
Stable angina pectoris: individuals with chest pain sec- 
ondary to coronary artery disease (>70% stenosis in one or 
more vessels) documented by cardiac catheterization. with a 
stable pattern in the 2 weeks before admission. 
Unstable ungina pectoris: individuals with coronary ar- 
tery disease documented by coronary angiography who were 
admitted with increased duration of typical angina1 attacks, 
angina with lesser degrees of activity or new onset angina1 
attacks. No electrocardiographic (ECG) changes or serum 
creatine kinase (CK) MB elevations diagnostic of myocardial 
infarction were present. Patients with postinfarction angina 
within 3 months of infarction were also included in this 
group. 
Acute myocardiul infarction: patients presenting with 
acute onset of chest pain or dyspnea within the 24 h before 
admission, with ST elevation on the ECG or an elevated 
serial CK level with an MB fraction >5%. 
The investigators were divided into wo groups: clinical 
and laboratory. The clinicians were blinded to the urinary 
fibrinopeptide A results and assigned the clinical diagnosis. 
The laboratory group determined urinary fibrinopeptide A 
levels without knowledge of the diagnosis. 
Sampling. Patients were asked to submit a urine sample 
on admission to the coronary care unit (sample I) and 2 and 
8 h after admission (samples 2 and 3). If the patient was 
unable to urinate, the next urine sample was collected and 
the time noted. In some patients with stable angina, only one 
urine sample could be obtained before catheterization. 
The urine (3 ml) was transferred into a collection tube 
containing 0.75 ml of an aqueous solution of sodium azide 
(0.2 mg), sodium citrate (22 mM), porcine intestinal heparin 
(Sigma H-7005, 200 units) and aprotonin (Sigma A-l 153,0.2 
TIUlml). The containers were stored at -70°C. 
Urinary fibrinopeptide A assay. Urine samples were as- 
sayed for fibrinopeptide A (Diagnostica Stago competitive 
enzyme-linked immunoassay, Asserachrom Iibrinopeptide 
A) and creatinine (Beckman, alkaline picrate method). 
Blood-positive urine samples were treated with bentonite to 
remove contaminating fibrinogen. All samples were treated 
with sodium phosphate buffer (final concentration 25 mM) to 
bring the pH to 7.5. 
Briefly, the assq’ wus as follows: Urinary librinopeptide 
A was bound to polyclonal rabbit antibody. The mixture was 
transferred to a microtiter well that was lined with fibrino- 
peptide A. The residual free antibody was bound to the 
microtiter well. The bound antibody was measured with a 
perioxidase-bearing antibody that had antirabbit gamma- 
globulin specificity. An inverse relation between antibody 
binding in the well and urinary fibrinopeptide A concentra- 
tion resulted, and the level of concentration was determined. 
Peroxidase activity was read on a Dynatech microtiter 
reader at a 490 mn wavelength. Modifications of the manu- 
facturer’s instructions included: I) the 0.75 ml of aqueous 
solution described: 2) reconstitution of the standard, cali- 
brating fibrinopeptide A with the same concentration of 
sodium phosphate buffer as that added to the test samples; 3) 
expansion of the standard curve to include higher urinary 
fibrinopeptide A concentrations; and 4) the standard curve 
was drawn as an iterative fit, not a straight line best fit, from 
optical density readings. All fibrinopeptide A results are 
expressed in IXtIIOgramS of fibrinopeptide A per milligram of 
creatinine (ngimg). 
Data analysis. Results are expressed as the admission 
value + SD and the highest value of multiple samples (peak 
value i SD). Peak values were not determined if only one 
sample was obtained. Statistical differences were assessed 
by using the Wilcoxon rank test for nonparametric groups, 
with probability (p) values <O.OS considered significant. 
Results 
Patient characteristics. There were 78 admissions of pa- 
tients with the diagnosis of myocardial infarction or unstable 
angina pectoris. In nine of these patients, no urine sample 
was obtained or the sample was obtained incorrectly. Six 
patients left the hospital before complete cardiac evaluation, 
and two patients had myocardial infarction of >24 h dura- 
tion. Eighteen patients were excluded for the following 
reasons: cancer (n = h), infection In = 5), inflammatory 
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Table 1. Clinical Characteristics of 63 Patients 
Control Stable Angina Unstable Angina Myocardial Infarction 
No. patients I3 (13) 20 (20) 20 (211 IO (12) 
(no. admissions) 
Age (pr) 46.1 ? 3.54 59.5 ? 6.7 620’97 68.6 + 7.W 
Gender (M/F) I Iv0 ISI 20’0 I OKI 
Aspirin usage 1 7 II) , 
Urea nitrogen (mgidl) IS.? ? IO.7 2 4 ? 16.3 25.6 5 16.4 
Plasma creatinine (mgi’dl) I .4 i 0.6 I.4 2 0.6 I.7 t I.1 
Platelets ( IO'imn?) 247 ?; .(I 27s i 9s 294 i 80 
*p < 0.001 compared wth stable angma. unstable angma and myocardial mfarctton groups. tp = O.OO? compared 
with stable angina group. F = female: M = male. 
disease (n = 2) and idiopathic dilated cardiomyopathy diag- 
nosed at subsequent cardiac catheterization (n = 5). There 
remained 43 admissions of patients with acute myocardial 
infarction of unstable angina. Among these 43 admissions, 5 
patients had negative findings at cardiac catheterization or 
on an exercise stress test, 5 had stable angina pattern, ?I had 
unstable angina (20 patients [I patient was admitted twice]) 
and 12 had a myocardial infarction (10 patients 12 patients 
were admitted twice]). 
The control group consisted of 13 patients, 5 with normal 
findings on cardiac evaluation after admission to the coro- 
nary care unit and 8 staff members without known coronary 
artery disease. The stable angina group consisted of 20 
patients, 5 admitted to the coronary care unit with a stable 
angina pattern and 15 consecutive patients admitted for 
elective cardiac catheterization. The unstable angina group 
consisted of 20 patients admitted to the coronary care unit. 
with 1 patient admitted twice, for a total of 21 admissions. 
The infarction group consisted of 10 patients. with 2 patients 
admitted twice, for a total of 12 admissions. Among these I?, 
there were 10 patients with transmural infarction (6 anterior. 
4 inferior wall) and 2 with non-Q wave infarction. In total. 63 
individuals were included in this study (Table I). 
In the control group, 12 of the 13 subjects provided 
multiple urine samples (total number of samples = 34) as did 
7 of the 20 patients with stable angina (total number of 
samples = 27). In the unstable angina group. 19 of the 2 I had 
multiple urine samples, as did I I of 12 patients with infarc- 
tion. 
Admission urinary fibrinopeptide A levels (Fig. 1). Admis- 
sion levels were similar in the control group (mean 3.3 * I .4 
ngimg creatinine, median 3.4) and stable angina group (mean 
3.2 ? 1.1 ngimg creatinine, median 3.2, p = NS) (Table 2). 
The mean admission urinary fibrinopeptide A level in the 
unstable angina group was 5.7 ? 2.6 ngimg creatinine 
(median 5.7), which was significantly higher than that in the 
control group (p = 0.008) and stable angina group (p < 
0.001). Values in the myocardial infarction group (mean 8.4 
% 10.0 ng/mg creatinine, median 5.8) were increased com- 
pared with those in the stable angina (p <: 0.001) and control 
(p = 0.005) groups, but not those in the unstable angina 
group (p = 0.64). 
Peak urinary fibrinopeptide A values (Fig. 2). Peak values 
in the control group (4.5 i I .9 ng!mg creatinine, median 4.8) 
Figure 1. Spot urinary fibrinopeptide A levels on admission in 
control (n = 13). stable angina (n = 20). unstable angina (n = 21) and 
acute myocardial infarction (n = I?) groups. 
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Table 2. Urinary Fibrinopeptide A Results in 63 Patients 
Admission Value Peak Value 
Control 3.3 2 1.4 (3.41 4.5 2 1.9 (4.8) 
Stable angina pectoris 3.2 + I.1 (3.2) 4.0 2 1.0 (3.8) 
Unstable angina pectoris 5.1 + 2.6 (5.7)* 7.6 f 5.9 16.2)+ 
Acute myocardial infarction 8.4 2 10.0 (5.8)* 44.5 ?I 60.0 (9.6)t 
*p < 0.01. p < 0.001 compared with control and stable angina groups. 
respectively; ip = 0.04 compared with stable angina group. fp < 0.001. p = 
O.OO?, p = 0.03 compared with control. stable angina and unstable angina 
groups, respectively. Data represent mean CT standard deviation) and median 
(indicated in parentheses) urinary fibrinopeptide A levels. All values are 
expressed in ng fibrinopeptide A/mg creatinine. 
and stable angina group (4.0 ? 1 .O ng/mg creatinine, median 
3.8) were similar (p = 0.47). In the unstable angina group, 
peak urinary fibrinopeptide A values (7.6 ? 5.9 nglmg 
creatinine, median 6.2) were increased over those in the 
stable angina (p = 0.04) and control groups, but did not reach 
I D’NS I 
I P’O.002 I 
r D=NS ” pa0.04 ” D’O.03 ’ 
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1 
. 
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statistical significance in the control group (p = 0.056). The 
two patients in the unstable angina group with the highest 
peak levels (1 I .6 and 29.2 ngimg creatinine) had a myocar- 
dial infarction on day 2 and day 4, respectively, of their 
hospital course. In the II patients with infarction who 
provided multiple samples, the mean peak urinary fibrin- 
opeptide A of 44.5 + 60.0 ngimg creatinine (median 9.6) was 
increased over the peak values in the unstable angina (p = 
0.03), stable angina (p = 0.002) and control (p < 0.001) 
groups. In three patients, peak urinary fibrinopeptide A 
levels > I25 nglmg creatinine were noted 10 to 18 h after the 
onset of chest pain (two transmural and one non-Q wave 
infarction). Serial urinary fibrinopeptide A values exhibited a 
more dynamic tendency in patients with infarction than in 
patients with unstable angina (Fig. 3). 
Incidence of elevated urinary fibrinopeptide A levels. The 
calculated mean value of all samples from the 13 control 
patients (n = 34) was 3.4 * 1.3 nglmg creatinine, and the 
Figure 2. Peak urinary fibrinopeptide A levels in the 
four patient subgroups. Asterisks indicate the two pa- 
tients with unstable angina who subsequently had a 
myocardial infarction. Dashed line represents the upper 
limit of normal for spot urinary fibrinopeptide A levels in 
this study. 
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Figure 3. The time course of 
fibrinopeptide A levels in pa- 
tients with coronary artery dis- 
ease. Patients with myocardial 
infarction show a more dynamic 
change in fibrinopeptide A lev- 
els over time. Dashed line shows 
the upper limit of normal. Aster- 
isks indicate the two patients 
with unstable angina who had 
infarction later in their hospital 
course. 
upper limit of normal urinary fibrinopeptide A in this study 
was established as 6.0 ngimg creatinine (control mean = 2 
SD). No control admission values were elevated, but 2 (17%) 
of I2 peak control values were >6.0 nglmg creatinine. No 
patient with stable angina had an elevated value. Ten (48%) 
of 21 patients with unstable angina had elevated admission 
values, and 10 (53%) of 19 patients exhibited increased peak 
levels. For patients with myocardial infarction, 6 (50%) of I2 
showed elevated admission values, and 10 (91%) of I I had 
increased peak values. The patient in the infarction group 
with consistently normal urinary fibrinopeptide A values had 
the smallest infarction (CK 203 IU, 5% MB). 
Discussion 
Plasma versus urinary levels of fibrinopeptide A. Fibrino- 
peptide A is a 16 amino acid peptide produced by the 
enzymatic cleavage of fibrinogen by thrombin (18). The 
resulting fibrin molecule. which lacks fibrinopeptide A, 
spontaneously polymerizes to form thrombus. Because ft- 
brinopeptide A production results from the action of throm- 
bin, it is a sensitive marker of thrombin activity and corre- 
lates with fibrin production. Fibrinopeptide A has a half-life 
of 3 to 5 min (12.15). Approximately 70% of the total 
fibrinopeptide A produced over 24 h is proteolytically de- 
graded by intra- and extravascular peptidases (15); the 
remaining 30% is filtered by the kidney. Most of the filtered 
fibrinopeptide A is, in turn. catabolized by renal tubular 
peptidases, but approximately 0.5% of plasma fibrinopeptide 
A is excreted in the urine (15). A significant correlation 
between plasma and 24 h urinary fibrinopeptide A levels in 
health and disease states has been shown (15.16). However, 
24 h urine collection is cumbersome, and an extended 
collection time obscures acute changes in fibrinopeptide A 
production. In addition. fibrinopeptide A immunoreactivity 
may decrease by as much as IS% over the 24 h collection 
period (17). Thus, spot urine sampling was evaluated (17) 
and shown to correlate significantly with simultaneously 
obtained plasma fibrinopeptide A levels (r = 0.97. p < 
0.0001). 
Elevated levels of fibrinopeptide A in acute myocardial 
infarction and unstable angina. This study shows that ele- 
vated spot urinary fibrinopeptide A levels are present in 
virtually all patients with acute myocardial infarction and 
approximately half of patients with unstable angina pectoris. 
Our data suggest that elevated urinary fibrinopeptide A 
levels in unstable angina and acute myocardial infarction 
may result from the presence of active thrombus formation 
in the coronary arteries. This study, the first evaluating spot 
urine samples, demonstrates that spot urinary fibrinopeptide 
A sampling is a sensitive method of determining active 
thrombus formation. In addition, this is the first study that 
has evaluated serial fibrinopeptide A levels, thereby demon- 
strating the dynamic course of fibrin deposition in patients 
with myocardial infarction and those with unstable angina 
whose condition progresses to myocardial infarction. The 
results concur with earlier studies (7-10.16) showing ele- 
vated plasma and 24 h urinary fibrinopeptide A levels in 
either unstable angina or myocardial infarction. 
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Relation to iutracorouary thrombus activity. In the pres- 
ent study, elevated peak urinary fibrinopeptide A values 
were found in 10 of 19 patients with unstable angina. The 
percent of elevated urinary fibrinopeptide A values is con- 
sistent with that reported in other studies (1,3,4) that angio- 
graphically evaluated the incidence of inlracoronary throm- 
bus in unstable angina. Our patients with unstable angina 
with consistently normal urinary fibrinopeptide A values 
may be those whose symptoms were not caused by throm- 
bus or in whom there was a lack of thrombus growth. The 
clinical utility of serial urinary fibrinopeptide A determina- 
tions may be to identify those patients with unstable angina 
whose symptoms result from intracoronary thrombus. 
Thrombolytic agents (4,5) or heparin (19.20) can reduce 
symptoms resulting from intracoronary artery thrombus 
formation, but these therapies are not without risks of 
bleeding or stroke. Thus, a noninvasive test that could 
determine the presence of thrombus may be helpful in 
stratifying those patients who would benefit from heparin or 
thrombolytic therapy. 
Of interest is the observation that the highest unstable 
angina urinary fibrinopeptide A values were found in the two 
patients who later had an infarction. High urinary fibrino- 
peptide A levels may indicate a state of high thrombotic 
activity that precedes coronary artery occlusion by throm- 
bus and may identify those patients at risk for myocardial 
infarction. 
Relation to myocardial infarction. All but one patient with 
myocardial infarction showed an increased peak urinary 
fibrinopeptide A value, and three patients had transient 
bursts of very high fibrinopeptide A activity (Fig. 3). The 
cause of the urinary fibrinopeptide A burst is unclear, but 
was unrelated to the location, size or type (transmural versus 
non-Q wave) of infarction. It is possible that a burst of 
fibrinopeptide A production occurred in all patients. but was 
observed in only three. Additional sampling may have 
revealed an increased incidence of burst activity. which may 
have been caused by increasing thrombus activity. 
In patients with myocardial infarction. the high peak 
values and dynamic urinary fibrinopeptide A changes over 
time may reflect ongoing intermittent thrombus formation 
(21) or myocardial tissue damage. In the canine model, 
extravascular cardiac fibrinogen has been shown 3 h after 
infarction (22). Although not yet demonstrated in human 
tissue, extravascular fibrinogen and subsequent fibrinopep- 
tide A production may have caused the increased peak 
urinary fibrinopeptide A values observed in patients with 
infarction. 
Limitations of study. Our study is somewhat limited in 
that simultaneous coronary angiography was not performed, 
SO there was no visualization of intracoronary thrombus. 
Coronary arteriography, however, is not an ideal method for 
determining the presence of intracoronary artery thrombus. 
as shown by the divergent results from studies (I ,3,4) using 
coronary angiography to evaluate the incidence of thrombus 
in unstable angina. In addition, Sherman et al. (2), evaluating 
coronary angioscopy in unstable angina, could identify only 
one of seven intracoronary artery thrombi by angiography 
alone. All seven arteries, however, contained thrombus 
when visualized by angioscopy. Given the reported incon- 
sistencies, we elected not to use coronary augiography as a 
reference standard, but instead selected our patients so that 
no other source of fibrinopeptide A elevation would be 
present. This approach is, in part, validated by the low 
number of elevated fibrinopeptide A levels observed in 
control subjects (2 of 34 total samples) and patients with 
stable angina (0 of 27 samples). Therefore, it is likely that 
elevated urinary fibriuopeptide A values reflected active 
coronary artery thrombus formation, although we cannot 
exclude increased extracoronary activity. 
Conclusions. As markers of thrombus formation, serial 
urinary fibrinopeptide A levels can be used in the evaluation 
of patients with acute ischemic heart disease. Serial sam- 
pling shows the dynamic course of fibrin formation in 
myocardial infarction. Spot urinary fibrinopeptide A deter- 
minations may aid in the early detection of those patients 
with unstable angina resulting from thrombus and those 
patients with unstable angina at the highest risk of infarction. 
Patients with unstable angina with elevated hbrinopeptide A 
levels may benefit from thrombolytic or heparin (23) therapy 
to abort impending infarction or progression of coronary 
artery disease. 
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